Previous Article | Next Article 
Molecular and Cellular Biology, June 1999, p. 4182-4190, Vol. 19, No. 6
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Identification of Id2 as a Globin Regulatory Protein by
Representational Difference Analysis of K562 Cells Induced To
Express
-Globin with a Fungal Compound
Melissa L.
Holmes,1,
John D.
Haley,2
Loretta
Cerruti,1
Wen-lai
Zhou,1
Helen
Zogos,1
David E.
Smith,2
John M.
Cunningham,3 and
Stephen M.
Jane1,*
Bone Marrow Research Laboratory, Royal
Melbourne Hospital, Parkville, Australia1;
Oncogene Science, Inc., Uniondale, New
York2; and St. Jude Children's Research
Hospital, Memphis, Tennessee3
Received 10 February 1999/Returned for modification 8 March
1999/Accepted 8 March 1999
 |
ABSTRACT |
A fungus-derived compound (OSI-2040) which induces fetal globin
expression in the absence of erythroid cell differentiation was
identified in a high-throughput drug discovery program. We utilized
this compound to isolate
-globin regulatory genes that are
differentially expressed in OSI-2040-induced and uninduced cells in the
human erythroleukemia cell line K562. Representational difference
analysis (RDA) of cDNA revealed several genes that were
significantly up- or down-regulated in OSI-2040-induced cells. One gene
whose expression was markedly enhanced was the gene for the
helix-loop-helix (HLH) transcription factor Id2. Southern analysis
of RDA amplicons demonstrated progressive enrichment of Id2 with each
successive subtraction of uninduced cDNA from induced cDNA. Northern
analysis of OSI-2040-induced K562 cells confirmed that Id2 expression
was directly up-regulated coordinately with
-globin. Analysis of
other inducers of fetal globin demonstrated up-regulation of Id2
with sodium butyrate but not with hemin. Retrovirus-mediated
overexpression of Id2 in K562 cells reproduced the enhancement of
endogenous globin expression observed with OSI-2040 induction.
Functional assays demonstrated that an E-box element in
hypersensitivity site 2 is required for Id2-dependent enhancement of
-promoter activity. Protein binding studies suggest that alterations
in E-box site occupancy by basic HLH proteins may influence this
activity, thus expanding the potential role of these factors in globin
gene regulation.
 |
INTRODUCTION |
The genes of the human
-globin
locus (
, G
, A
,
,
) are regulated
in a developmental and tissue-specific manner. Inherent to this control
are cis-acting promoter sequences which flank the genes
themselves and distal regulatory sequences which reside 6 to 20 kb 5'
of the
-gene, known as the locus control region (LCR). The
coordinate action of the LCR and globin gene promoters results in high
levels of expression of the individual genes at distinct developmental
stages. The
-gene is expressed during embryonic erythropoiesis and
the
-genes are expressed during fetal development, while expression
of the
- and
-genes is confined to adult erythroid cells
(42). Studies of the globin promoters and the four
erythroid-cell-specific DNase I hypersensitivity sites (HS1 through -4)
which define the LCR have identified numerous protein-binding motifs
for a variety of ubiquitous (Sp1, USF, YY1, and others) and
erythroid-cell-specific (GATA-1, NF-E2, EKLF, and others) transcription
factors (20, 35). Many of these proteins have been
identified through recognition of their cognate binding sites in globin
regulatory regions, although several have been defined through
biochemical purification or molecular cloning techniques. These
proteins are thought to act as transcriptional activators or modifiers
of the chromatin structure of the locus. Despite these important
functions, few of these factors have been shown to have discriminatory
roles in the regulation of specific globin genes. EKLF is one exception
to this, as mice nullizygous for the EKLF gene retain normal embryonic
and fetal globin expression but die of a
-thalassemic illness at the
onset of adult hematopoiesis (34, 37). Another exception
appears to be the stage selector protein, which binds to the proximal
-promoter and preferentially recruits the LCR during fetal
erythropoiesis (21, 22).
The existence of other factors capable of altering the developmental
profile of the
-globin cluster is suggested by studies of a diverse
group of genetic mutations unified phenotypically by persistent fetal
globin expression after birth. These mutations are known collectively
as hereditary persistence of fetal hemoglobin (HPFH) and are largely
due to point mutations in the
-promoter that alter the binding of
transcriptional activators or repressors (39). However,
several kindred have been identified with HPFH that is not linked to
the
-globin cluster, indicating the presence of as-yet-unknown
trans-factor mutations that influence the developmental profile of
-gene expression (12, 14). These factors may
not be tissue-specific or developmentally restricted in their
expression patterns but may exert their influence by augmenting the
transcriptional activity of an already active
-promoter. The
importance of such factors lies in the observation that elevated levels
of fetal hemoglobin have a protective effect on patients who inherit
the devastating
-chain disorders
-thalassemia and sickle-cell
disease (33). Hence, the identification of proteins capable
of inducing fetal globin gene expression may provide treatment
alternatives for these disorders through gene therapy or
pharmacological strategies.
One approach to identifying these novel factors is the study of
compounds that induce
-gene expression in vitro or in vivo. To this
end, we recently identified a fungus-derived compound (OSI-2040) which
enhances
-globin gene expression in the human erythroleukemia cell
line K562 (29). This fungus-derived compound was found in a
high-throughput robotic drug screen designed to identify agents which
specifically transcriptionally activate target genes. The activity of
this compound is comparable to that of the other potent
-globin
inducers, sodium butyrate and hydroxyurea. In this study, we employed
representational difference analysis (RDA) of cDNA to identify genes
differentially expressed coordinately with
-gene induction by
OSI-2040. Our results demonstrate that transcription factor Id2, a
member of the helix-loop-helix (HLH) family of proteins, is
up-regulated in OSI-2040-induced K562 cells. Retrovirus-mediated
overexpression of Id2 in K562 cells reproduces the induction of
-gene expression observed with OSI-2040, suggesting that this factor
may play a direct role in the regulation of the
-globin cluster.
 |
MATERIALS AND METHODS |
Isolation of OSI-2040.
A library of fungal broth extracts
(OSI Pharmaceuticals, Inc.) was screened against a stable human
erythroleukemia cell line, K562, containing an HS2-
-luciferase
reporter gene. A total of 54,656 entities were screened. The fungal
extract file yielded 460 hits from 378 different organisms. Compounds
were prioritized on the basis of efficacy, potency, and cytotoxicity at
24- and 48-h exposure time points for bioassay-guided fractionation and purification by sequential organic extraction, reverse-phase
high-pressure liquid chromatography (HPLC), and countercurrent liquid
phase chromatography. The biological activity of pure compounds was further characterized by tissue culture (see Results), while the compound structures were determined by mass spectrometry and nuclear magnetic resonance imaging. OSI-2040 increased
-globin transcription and
-globin protein expression in three distinct assays: a
hemoglobin-staining assay, a fetal hemoglobin (HbF) enzyme-linked
immunosorbent assay, and a cation-exchange HPLC assay (16).
Cell lines.
The human erythroleukemia cell lines K562 and
HEL were grown in RPMI medium supplemented with 10% fetal calf serum.
Cells were induced with OSI-2040 at 0.8 mM, 25 mM hemin, or 1 mM sodium butyrate for 48 h prior to RNA extraction. The human embryonal kidney cell line 293T and the human hepatocellular carcinoma cell line
Hep3B were grown in Dulbecco's modified Eagle medium supplemented with
10% fetal calf serum.
RNA isolation and Northern analysis.
Two methods were used
to isolate poly(A)+ RNA. For RDA, total RNA was isolated
from 5 × 107 K562 cells by guanidinium isothiocyanate
lysis (RNAzol; Biotecx Laboratories, Inc.) as described by the
manufacturer. Polyadenylated RNA was then isolated with biotinylated
oligo(dT) primers and streptavidin coupled to magnetic particles
(PolyATract; Promega). Aliquots of 2 mg of poly(A)+ RNA
were converted to cDNA by using an oligo(dT) primer and the RiboClone
cDNA synthesis system (Promega).
For Northern analysis, poly(A)+ RNA was isolated from pools
of 2.5 × 107 K562 cells with oligo(dT) cellulose
(Boehringer). Northern analysis was performed as previously described
(41).
RDA of cDNA.
Analyses of cDNAs prepared from drug-induced
and uninduced K562 cells were performed as previously described with
minor adjustments (19, 27). K562 cells were induced with
OSI-2040 (0.8 mM) for 48 h, and RNA and cDNA were prepared as
detailed above. Prior to the initial subtractive hybridization,
DpnII-digested cDNA fragments were electrophoresed on a 1%
agarose gel, transferred to a nitrocellulose filter, and probed with
-actin to normalize the pools. The tester and driver amplicons were
hybridized to each other at molar ratios of 1:100, 1:400, and 1:80,000
for each successive round of RDA. The driver amplicons derived from
uninduced cells were spiked with the
-globin cDNA. After three
rounds of hybridization and PCR, discrete DNA bands visualized on 1%
agarose gels were excised, isolated, and cloned into the
BamHI site of M13 mp19. They were then sequenced with an ABI
dideoxy terminator cycle sequencer (Applied Biosystems) and compared to
the GenBank and expressed sequence tag (EST) databases by using BLAST algorithms.
Reverse Northern blotting.
The M13 mp19 clones of the RDA
fragments (100 ng) were blotted onto Genescreen Plus membranes in
duplicate with a slot blot apparatus (Schleicher and Schuell).
Fragments from several housekeeping genes (actin, S14, and ribosomal
protein genes) were also included. The membranes were baked for 2 h at 80°C. Equivalent amounts of uninduced and drug-induced K562
cDNAs were radiolabelled by reducing the concentration of dCTP in the
PCR to 42.5 mM and including 5 ml of [
-32P]dCTP in a
12-cycle PCR (95°C for 1 min and 72°C for 3 min). The labelled
cDNAs were then purified through a Sephadex G-50 column (Pharmacia) and
hybridized with filters as previously described (41). The
signals from housekeeping genes were compared to ensure that cDNA
probes with similar specific activity had been used.
Isolation of Id2 coding sequence.
The Id2 coding sequence
was amplified from an
ZAP K562 library with the primers 5'
CGGTCTCGAGTTCCTCGCGGTC and 3'
GAACCTCGAGTATTCAGCCACACAGTG, which correspond to nucleotides
72 to 93 and 488 to 514 (Genbank sequence HUMID2HC), respectively
(44). The primers also incorporate an XhoI site
for subsequent cloning. The first-round PCR included 200 ng of library
DNA, 100 pmol of vector primer and 3' Id2 primer, 0.4 mM
deoxynucleoside triphosphates, 1 U of Taq polymerase, and 1× Taq buffer (Boehringer). PCR conditions were 95°C for
30 s, 55°C for 1 min, and 72°C for 1 min for a total of 33 cycles. Nested PCR was then performed with 1 ml of the first-round
reaction product with both Id2-specific primers for 25 cycles. The
integrity of the final PCR product was confirmed by sequencing as
detailed above.
Generation of amphotropic retroviral supernatant and transduction
of K562 cells.
The Id2 coding region was cloned into the
retroviral vector plasmid MSCV-HA at a unique XhoI site
(17, 38). This bicistronic vector contains (i) the murine
stem cell virus (MSCV) 5' long terminal repeat, (ii) a hemagglutinin
(HA) epitope tag with the Id2 coding sequence in frame, (iii) the
encephalomyocarditis internal ribosomal entry site (IRES), (iv) the
green fluorescent protein (GFP) cDNA, and (v) the MSCV 3' long terminal
repeat (see Fig. 5A). The plasmid was cotransfected with an amphotropic
packaging plasmid into 293T cells by calcium phosphate precipitation.
After 48 h, the supernatant containing the amphotropic particles
was harvested, filtered, and added to either K562 or HEL cells every 12 h for 3 days. The K562 cells were allowed to recover for
72 h and then were analyzed for GFP expression by flow cytometry. The highest-expressing 10% of cells were sterilely sorted and subsequently expanded in pools. A biological titer of the supernatant on NIH 3T3 cells was equivalent to a concentration of 106
CFU/ml.
Oligonucleotides, nuclear extract, and EMSA.
The sequences
of the top strand of the duplex oligonucleotides used for an
electrophoretic mobility shift assay (EMSA) were the 8762 E-box
sequence (CTAGAGGGCAGATGGCAA) and the USF consensus site
(CACCCGGTCACGTGGCCTACACC). Nuclear extract of K562 cells was
prepared by Dounce homogenization of isolated nuclei and utilized in
EMSA as described previously (21).
DNA construction and transfection.
Constructs containing the
HindIII-XbaI fragment of HS2 linked to the
-promoter-luciferase gene or
-promoter-luciferase gene have
been described previously (1). Constructs containing the mutant 8701 or 8762 E boxes were described in reference
15. Transient-transfection experiments were repeated
six times with at least two independent preparations of DNA, as
described previously (2). Reporter assays were performed
with the luciferase assay kit from Promega according to the
manufacturer's instructions.
 |
RESULTS |
Identification and preliminary characterization of
OSI-2040.
OSI-2040 is a fungus-derived compound
identified as part of a proprietary high-throughput drug screening
program designed to isolate novel agents which could induce fetal
globin production (see Materials and Methods for details of isolation
and purification). In the initial screening approach, a K562 cell line
stably transfected with an artificial promoter construct containing the
HS2 region of the LCR and a
260
-promoter fused to the luciferase
gene was used (Fig. 1A). Transcriptional
activity of the
-promoter was increased in these cells in response
to exposure to OSI-2040 for 24 h in a dose-dependent manner (Fig.
1B). No increase in the activity of a control bcr
promoter-reporter in OSI-2040-induced K562 cells or of a control
erythropoietin promoter-reporter in OSI-2040-induced Hep3B cells was
observed (data not shown). To examine the effects of OSI-2040 in the
context of the endogenous
-globin genes, K562 cells were exposed to
the drug for 96 h and stained with benzidine. Cells treated with
hydroxyurea and sodium butyrate served as controls. As seen in Fig. 1C,
globin synthesis increased with all three agents. These findings were
confirmed by HbF enzyme-linked immunosorbent assay and combined
HPLC-mass spectrometry studies (data not shown).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
OSI-2040 increases -promoter activity and endogenous
fetal globin expression. (A) Diagrammatic representation of the
HS2- -luciferase construct used for screening compounds from fungus
libraries. The open box represents the
HindIII-BglII fragment of HS2, and the shaded
box represents the 260 -promoter-luciferase reporter gene. (B)
Dose-response curve of -promoter induction with OSI-2040. K562 cells
containing the HS2- -luciferase construct were exposed to increasing
concentrations of OSI-2040 as indicated. After 24 h, the cells
were lysed and the reporter gene activity was measured and plotted as
the induction compared with that of uninduced control K562 cells. The
OSI-2040 dose axis is not to scale. (C) Benzidine staining in cells
treated with -gene inducers. K562 cells were treated with OSI-2040
(0.8 mM), butyrate (1 mM), or hydroxyurea (500 mM) for 96 h.
Untreated K562 cells served as a control.
|
|
RDA of cDNA of OSI-2040-induced and uninduced K562 cells.
Based on these findings, we proposed that OSI-2040 might be acting
through a transcriptional mechanism involving a regulator of
-gene
expression. To identify a putative factor involved in this process, we
performed RDA of cDNA, a PCR-based subtraction strategy on mRNA from
OSI-2040-induced and uninduced K562 cells (see Materials and Methods).
This procedure was performed with uninduced mRNA subtracted from
induced mRNA to detect transcripts which were up-regulated by OSI-2040
(forward direction) and with induced RNA subtracted from uninduced RNA
to detect suppressed transcripts (reverse direction). As seen in Fig.
2A, the complexity of the cDNA species
decreased with successive rounds of subtraction and amplification in
both directions. Discrete bands were then excised from agarose gels and
cloned. To determine whether the isolated cDNAs were truly
differentially expressed, a reverse Northern analysis was
performed. As shown in Fig. 2B, the majority of clones isolated in the
forward direction showed significant up-regulation (2- to 16-fold) in
the induced cDNA pool. Clones isolated in the reverse direction were
down-regulated in the induced pool (3- to 15-fold), indicating that
both subtractions had identified differentially expressed genes. The
identity of these genes was determined through sequence analysis and
BLAST database searches. As seen in Table
1, a variety of clones was obtained, many
with a role in cell-signaling pathways or cell cycle regulation. Of note was the isolation of an up-regulated transcription factor, Id2, in
the induced pool.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 2.
RDA of cDNA of uninduced and OSI-2040-induced K562
cells. (A) Ethidium bromide-stained agarose gels showing RDA amplicons.
Lanes and +, cDNAs from uninduced and OSI-2040-induced K562
cells. Lanes F1 to F3 represent successive rounds of subtraction in the
forward direction with induced K562 cDNA as the tester and uninduced
K562 cDNA as the driver. Lanes R1 and R2 represent successive rounds of
subtraction in the reverse direction with uninduced K562 cDNA as the
tester and induced K562 cDNA as the driver. The migration of molecular
weight standards is indicated. (B) Slot blot hybridization of 22 clones
demonstrating differential representation between uninduced and induced
amplicons. Actin, which is not differentially expressed, was used as a
control.
|
|
Id2 is up-regulated in OSI-2040-induced K562 cells.
To
validate that Id2 was differentially enriched during RDA, cDNA
amplicons obtained at each step of the forward and reverse procedures
were analyzed by Southern blotting with a full-length Id2 cDNA probe.
As seen in Fig. 3A, no signal was
observed in uninduced (lane
) K562 cells or in amplicons derived from
one or two rounds of reverse subtraction (lanes R1 and R2). In
contrast, the Id2 signal was apparent after drug treatment alone (lane
+), with dramatic enhancement observed with sequential subtraction in
the forward direction (lanes F1 to F3). To directly assess the effects
of OSI-2040 treatment on Id2 expression, K562 cells were cultured in
the presence of the drug for 48 h, and mRNA was prepared. As seen
in Fig. 3B, Northern analysis revealed a significant up-regulation of
Id2 in this setting. Concomitant up-regulation of endogenous
-gene
expression was also evident with OSI-2040 treatment. In contrast, other
markers of erythroid-cell differentiation, including GATA-1 and
glycophorin A, were not increased (data not shown). To assess the
effects of OSI-2040 on other globin genes, we performed Northern
analysis on induced K562 cells with
-,
-, and
-globin probes.
Interestingly, a significant induction of
-gene expression was
observed. No induction of either
- or
-globin expression was seen
(Fig. 3C). We also examined the effects of OSI-2040 on another human
erythroleukemia cell line, HEL, which constitutively expresses fetal
globin genes. No induction of Id2 or
-gene expression was observed
with Northern analysis of this line. Reverse transcription-PCR analysis
of uninduced and induced HEL mRNA revealed that Id2 was not expressed
in this line (data not shown).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Id2 and -globin are up-regulated in OSI-2040-induced
K562 cells. (A) Southern blot of the cDNA pools and amplicons shown in
Fig. 2A obtained with an Id2 probe. Lanes and +, cDNA from
uninduced and OSI-2040-induced K562 cells. Lanes F1 to F3
represent successive rounds of subtraction in the forward
direction with induced K562 cDNA as the tester and uninduced K562 cDNA
as the driver. Lanes R1 and R2 represent successive rounds of
subtraction in the reverse direction with uninduced K562 cDNA as the
tester and induced K562 cDNA as the driver. (B) Northern analysis of
OSI-2040-induced K562 cells. Two milligrams of poly(A)+ RNA
from uninduced ( ) or OSI-2040-induced (+) K562 cells was
analyzed with -gene and Id2 probes. S14 served as the control. (C)
Northern analysis of OSI-2040-induced K562 cells. Two milligrams of
poly(A)+ RNA from uninduced ( ) or OSI-2040-induced (+)
K562 cells was analyzed with -gene, -gene, and -gene probes.
S14 served as the control.
|
|
To determine whether other compounds capable of inducing fetal globin
expression also induced Id2, we performed Northern analysis
on K562
cells treated with sodium butyrate or hemin. As seen in
Fig.
4, butyrate induced a significant
increase in Id2 expression
with a concomitant increase in

-globin
message (lane 2). In contrast,
hemin failed to induce Id2 expression,
despite effectively increasing
the levels of

-gene transcripts (lane
3). Quantitation of these
results revealed that OSI-2040 induced

-globin 4.9-fold and Id2
11-fold, whereas butyrate induced

-globin 2.9-fold and Id2 7.9-fold
when corrected for expression of
the housekeeping gene S14. These
results further indicated that a
significant correlation existed
between Id2 and

-gene induction.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 4.
Id2 is induced by sodium butyrate but not hemin.
Northern analysis of butyrate- or hemin-induced K562 cells is shown.
Two milligrams of poly(A)+ RNA from uninduced K562 cells or
K562 cells induced with either butyrate or hemin (as indicated) was
analyzed with -gene and Id2 probes. S14 served as the control.
|
|
Overexpression of Id2 in K562 cells induces
-gene
expression.
To directly test whether Id2 alone could induce
-gene expression, we constructed an MSCV-based retroviral vector
containing Id2 cDNA. This bicistronic vector contains the GFP cDNA
linked by the encephalomyocarditis IRES to the Id2 cDNA tagged with an HA epitope (Fig. 5A). The K562 cells were
transduced with an amphotropic retrovirus derived from this vector, and
positive cells were selected by repeated fluorescence-activated cell
sorter sorting for green fluorescence (Id2+ K562 cells).
Cells transduced with the MSCV vector lacking the Id2 cDNA served as
the control (Id2
K562 cells). Multiple pools of
Id2+ and Id2
K562 cells were obtained and
analyzed by Northern analysis. As seen in Fig. 5B, a significant
increase in Id2 expression was observed in all pools transduced with
the Id2-containing vector (mean, 15-fold). Reprobing of the Northern
blot with a
-gene-specific probe demonstrated a concomitant increase
in expression of the
-gene in all Id2+ K562 cell pools,
compared with controls (mean, fourfold). No increase in SCL, GATA-1, or
E12 expression was observed (data not shown). Similar results were also
obtained in a second
-globin-expressing cell line, HEL, with a
threefold induction of
-gene expression observed in Id2+
lines compared with controls (data not shown). Western analysis of the
Id2+ K562 cell pools demonstrated Id2 protein expression in
all pools (Fig. 5C). Northern blotting analyses to examine the direct
effect of Id2 on
- and
-gene expression were also performed. As
seen in Fig. 5D,
-gene expression was induced to a level similar to that of the
-gene. No induction of
-gene expression was observed.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 5.
Overexpression of Id2 in K562 cells induces -gene
expression. (A) Diagrammatic representation of the
MSCV-Id2-IRES-GFP retroviral vector. The vector consists of the MSCV
retroviral backbone, containing the Id2 coding sequence, followed by an
IRES from the encephalomyocarditis virus linked to the GFP gene.
(B) Northern analysis of K562 cell pools overexpressing Id2. Two
milligrams of poly(A)+ RNA from K562 cells transduced with
MSCV-Id2 or MSCV alone were analyzed with -gene and Id2 probes. S14
served as the control. (C) Western analysis of K562 cell pools
overexpressing Id2. Whole-cell lysates from K562 cells transduced with
MSCV-Id2 or MSCV alone were analyzed with anti-HA
antisera. The specific HA-Id2 band is shown by an arrow. Numbers on the
right represent the migration pattern of protein molecular weight
standards (in thousands). (D) Northern analysis of K562 cell pools
overexpressing Id2. Two milligrams of poly(A)+ RNA
from K562 cells transduced with MSCV-Id2 or MSCV alone was analyzed
with -gene and -gene probes. S14 served as the control.
|
|
An E-box motif in HS2 is essential for Id2-dependent enhancement of
-promoter activity.
As Id2 functions as a dominant negative
regulator of basic HLH (bHLH) proteins by preventing their binding to
E-box motifs, we examined our initial screening construct
(HS2-
-luciferase) for likely sites of Id2 activity. Although no
E-box elements in the globin promoters have been described, recent
studies have documented the importance of conserved E-boxes in HS2 for
enhancer function. These elements are located within the HS2 core at
positions 8701 and 8762 (15, 24). Our observation that Id2
induced both
- and
-gene expression, but not
-globin
expression, further suggested that HS2 may contain the sequences that
mediate the Id2 effect. As a component of the LCR, HS2 is involved in
the regulation of all the
-like genes but plays no role in
-globin induction. We therefore ascertained whether the HS2 E-box
sequences were critical for Id2-dependent enhancement of
-promoter
inducibility. Id2+ and Id2
K562 cell pools
were transfected with a construct containing wild-type HS2 linked to a
-promoter-luciferase reporter gene hybrid or with constructs in
which either the 8701 or 8762 E boxes in HS2 had been mutated and
linked to the reporter (Fig. 6A). As
shown in Fig. 6B, induction of
-promoter activity was observed with
both the wild-type HS2 and 8701 E-box mutant HS2. In contrast, mutation
of the 8762 E-box motif reduced the Id2-dependent induction of
-promoter activity. This effect was observed without loss of
activity of the uninduced construct (reference 24
and data not shown). To examine these findings in the context of
protein binding, an EMSA was performed by using the 8762 region as the probe. As seen in Fig. 6C (lane 1), a number of protein-DNA complexes were observed with extract derived from the Id2
K562
cells. These complexes were also observed in extract from Id2+ cells (lane 2) with the exception of complexes A and
B, which were absent from the Id2+ K562 cell extract.
Previous studies suggested that the presence of complex B may be due to
binding of the bHLH protein USF (15). To confirm this,
excess unlabelled oligonucleotide containing the USF consensus sequence
was added to extract from the Id2
cells. As seen in lane
3, complex B was selectively disrupted by this process. Complex A was
not reduced by the USF oligonucleotide and actually appeared to be
enhanced in this setting.



View larger version (83K):
[in this window]
[in a new window]
|
FIG. 6.
An E box in HS2 mediates Id2 induction. (A) Diagrammatic
representation of the constructs used for transfection into
Id2+ and Id2 K562 cells. Wild-type HS2
contains the HindIII-XbaI fragment of HS2
linked to the 260 -promoter-luciferase gene hybrid. Conserved and
protein binding sites within HS2 are labelled. Mutated sites are
denoted by solid black circles. (B) Fold induction of the constructs
depicted in panel A. The fold increase in luciferase levels between
Id2 and Id2+ K562 cells is shown for each
construct. Luciferase values were corrected for the protein
concentration of the lysate. Values are the means of at least three
separate transfections of more than 50 pools with at least two
different plasmid preparations. (C) Binding of proteins to the 8762 E
box. EMSA was conducted with nuclear extracts from Id2
(lanes 1 and 3) and Id2+ (lane 2) K562 cells. A USF probe,
used as an unlabelled competitor, was added to lane 3 in 50-fold molar
excess.
|
|
 |
DISCUSSION |
We have identified a role for the HLH transcription factor Id2 in
the regulation of human globin gene expression. The conduit for this
finding was a fungus-derived compound, OSI-2040, which induces
-gene
expression in K562 cells. This compound was defined in a
high-throughput drug screen designed to isolate compounds that
transcriptionally activate target genes. Based on this, we postulated
that the subtraction of differentially expressed genes in
OSI-2040-induced and uninduced K562 cells may identify novel factors
that mediate the induction of
-globin gene expression. A similar
approach has been employed to identify genes responsive to a variety of
stimuli (5, 9, 26). One advantage of our approach is that
the starting material for subtraction is derived from identical K562
cells, which differ only in their exposures to OSI-2040. This is
critical for minimizing the isolation of false-positive clones. When
the powerful RDA subtraction strategy was used, Id2 was isolated as a
transcription factor whose expression was coordinately up-regulated
with the
-gene in OSI-2040-induced cells. Although other
differentially expressed genes were also identified, they appeared to
involve signaling pathways or cell cycle regulation. These genes were
presumably involved in drug activation pathways but were unlikely to be
involved in the direct activation of the
-promoter. The absence of
-globin cDNA amplification in the RDA process was attributable to
the addition of
-globin cDNA to the driver amplicons at each
subtraction step.
Our interest in Id2 as a potential globin regulatory protein was
heightened by two observations further linking Id2 and
-gene induction. Firstly, the fetal erythroid cell line, HEL, in which
-gene induction was not initiated by OSI-2040, also did not express Id2. Secondly, sodium butyrate, a potent fetal-globin-inducing agent,
also markedly induced Id2 expression in K562 cells. Sodium butyrate is
thought to increase
-globin expression through a direct
transcriptional mechanism in concert with its activity as a histone
deacetylase inhibitor (6, 30). Several investigators have
localized putative sodium butyrate target sequences in the
-promoter
(30, 36). In addition, a small region of HS2 that includes
the core NF-E2 sites has also been implicated in sodium butyrate
response (40). Studies of the E-box region of HS2 with sodium butyrate have not been performed, and the demonstration of
enhanced Id2 expression is also novel in this context. Interestingly, at the completion of these studies, structural analysis of OSI-2040 revealed that it was identical to a previously described fungal compound, apicidin, which also functions as a potent histone
deacetylase inhibitor (13). The mechanism by which these
histone-modifying agents induce Id2 expression was not addressed in our
study. One possibility is that acetylation of histones in core
nucleosomes assembled on the Id2 promoter results in enhanced
transcription-factor binding to this region and in consequent gene
activation (46). A similar mechanism could also occur on the
- and
-promoters, resulting in local perturbation of the
chromatin structure, which, when combined with the effects of Id2 on
protein binding to the LCR, could alter the interaction between
enhancer-bound proteins and the promoter (43).
Alternatively, the effect of Id2 on the LCR could be reflected in the
up-regulation of
- and
-globin expression, as these genes are
permissive in the embryonic and fetal environments of the K562 cell.
In contrast to OSI-2040 and sodium butyrate, hemin induction of
-gene expression did not involve up-regulation of Id2. This finding
suggests that induction of erythroid-cell differentiation alone is
insufficient for increasing the levels of Id2. In support of this,
observations of cultured human hematopoietic progenitors demonstrate
that Id2 expression is down-regulated at the onset of erythroid-cell
differentiation (10). Subsequent up-regulation of Id2 occurs
only during late erythroid-cell maturation (10, 11).
Conversely, OSI-2040-induced K562 cells and Id2+ K562 cells
did not exhibit other features of erythroid-cell differentiation, with
no observed increase in glycophorin A, SCL, or GATA-1 levels. These
findings are similar to those of previous studies, which demonstrated
that enforced overexpression of Id genes inhibits differentiation of a
variety of hematopoietic cell lineages (23, 28, 45).
Interestingly, addition of Id2 antisense oligonucleotides to human
progenitor cells significantly increases erythroid-cell colony
formation, suggesting that Id2 has a negative role in erythroid-cell differentiation (10). This finding further strengthens our
hypothesis that the increase in embryonic and fetal globin expression
is due to a direct transcriptional effect of Id2, rather than to an
effect mediated by influences on the erythroid-cell differentiation program.
The transcriptional effects of Id2, a member of the HLH protein family,
are thought to be secondary to sequestration of the closely related
bHLH family of proteins (4, 44). The bHLH family consists of
numerous ubiquitous (E12, E47, and USF) and cell-specific (SCL and
MyoD) factors involved in cell fate and differentiation (3, 25,
31, 32). DNA binding of these factors occurs through the
formation of obligate homo- or heterodimers on a consensus E-box motif
(18, 47). Id2 lacks the basic amino acid domain of the bHLH
proteins which is essential for DNA binding, and hence heterodimers of
Id2 and bHLH proteins fail to assemble on E-box sites (4).
Recent studies have examined the role of E boxes in HS2 in the
induction of fetal and embryonic globins (15, 24). They have
identified two E-box sequences at positions 8701 and 8762 in the core
region of HS2, which are conserved between species. As the original
construct used in the screen for OSI-2040 contained HS2 linked to the
260
-promoter and as extensive protein binding studies of the
-promoter have failed to identify bHLH binding sites, we postulated
that the effects of Id2 may be mediated, in part, through the E boxes
in HS2. The induction of
-gene expression observed with OSI-2040 and
the lack of
-gene induction further supported a role for HS2 in this
process. Our functional studies suggest that Id2 induction of
-promoter activity is dependent on the presence of an intact E-box
motif at position 8762 in HS2. Although mutation of this site does
little to affect the enhancer activity of HS2 with either
- (our
studies and reference 24) or
-promoters
(15) in wild-type cells, in Id2+ cells induction
of the
-promoter is lost. One explanation of this finding is that a
balance of positive and negative regulators exists at the 8762 site.
Mutation of the site ablates binding of both of these classes of
factors, and thus, no net effect on enhancer activity is observed
(15). In the presence of increased Id2, the balance is
altered by the selective sequestration of a negative regulator, thereby
mediating increased enhancer activity. Examination of the protein
binding data with the 8762 E-box probe supports this hypothesis. Two
complexes (A and B) are significantly altered in the Id2+
K562 cells compared to wild-type cells (Fig. 6C). While the identity of
complex A remains unknown, complex B contains USF, which has recently
been shown to act as a negative regulator in a highly functionally
analogous enhancer system. Studies of the immunoglobulin heavy-chain
enhancer demonstrate that USF functions as a negative regulator by
competing with other bHLH proteins for occupancy of a key E-box element
(7). As USF lacks a potent trans-activation domain, its binding to the enhancer E box creates a dominant negative effect. Although homodimeric USF is not one of the bHLH complexes known
to be regulated by Id2 (44), the binding of USF to the 8762 site appears to be heterodimeric (15). Thus, the
displacement of this protein complex may be mediated by Id2 interacting
with the heterodimeric component of the complex. Although no new
activator complex is observed with the 8762 probe with the displacement of USF binding, EMSA is performed in the presence of vast probe excess.
Therefore, any of the existing complexes defined by Elnitski et al.
could play the role of unopposed transcriptional activator (15). The ability of Id2 to stimulate gene transcription has also been examined in studies of the low-affinity nerve growth factor
receptor (p75LNGFR) gene promoter. Binding of the bHLH factor ME1a to an E box in the LNGFR promoter specifically
represses promoter activity in a variety of cell lines, including PC12, a pheochromocytoma line. Coexpression of Id2 and ME1a in PC12 results
in the formation of a non-DNA binding heterodimer with alleviation of
ME1a-dependent repression. In this context, promoter activation is
achieved through other E-box binding proteins which are unaffected by
Id2 (8). These findings are similar to our own and
demonstrate that the Id-like transcriptional regulators function as
either repressors or activators, depending on the sequence context and
on the balance of bHLH proteins which act on a specific site.
Although Id2 is capable of enhancing embryonic and fetal globin
expression in cells in which the genes are normally transcribed, it
remains to be determined whether Id2 can exert the same effect on
transcriptionally inactive
- and
-genes. Our results,
demonstrating a failure of Id2 to induce
-gene expression in K562
cells, suggest that only target promoters that are transcriptionally
active will be responsive. Thus, the effects of Id2 are not truly
developmentally specific but are dependent on the transcriptional
environment of potential target genes. Nevertheless, induction of Id2
expression in the context of active fetal globin expression in primary
human cord blood progenitors may generate an HPFH phenotype in which
-gene expression is unable to be silenced. Ongoing studies will determine the potential of Id2 for genetic therapy approaches to the
-hemoglobinopathies.
 |
ACKNOWLEDGMENTS |
We thank Ross Hardison and Robert Hawley for the gift of plasmids
and A. W. Nienhuis for continuing support. We thank Adam Chapman
for technical assistance. We also thank Ping Cai for natural product
purification and Cedric Pieric for fungal fermentation support.
This work was supported by the NHMRC of Australia, The Wellcome Trust
(S.M.J.), NIH grant PO1 HL53749-03, Cancer Center Support CORE grant
P30 CA 21765, and the American Lebanese Syrian Associated Charities (ALSAC).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Bone Marrow
Research Laboratory, c/o Royal Melbourne Hospital Post Office,
Parkville, VIC, Australia 3050. Phone: 61-3-934 28641. Fax: 61-3-934 28634. E-mail: jane{at}wehi.edu.au.
Present address: Department of Hematology Research, Prince of Wales
Hospital, Randwick, NSW, Australia 2031.
 |
REFERENCES |
| 1.
|
Amrolia, P. J.,
J. M. Cunningham, and S. M. Jane.
1998.
Maximal activity of an erythroid-specific enhancer requires the presence of specific protein binding sites in linked promoters.
J. Biol. Chem.
273:13593-13598[Abstract/Free Full Text].
|
| 2.
|
Amrolia, P. J.,
J. M. Cunningham,
P. Ney,
A. W. Nienhuis, and S. M. Jane.
1995.
Identification of two novel regulatory elements within the 5'-untranslated region of the human Ag-globin gene.
J. Biol. Chem.
270:12892-12898[Abstract/Free Full Text].
|
| 3.
|
Begley, C. G.,
P. D. Aplan,
S. M. Denning,
B. F. Haynes,
T. A. Waldmann, and I. R. Kirsch.
1989.
The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif.
Proc. Natl. Acad. Sci. USA
86:10128-10132[Abstract/Free Full Text].
|
| 4.
|
Benezra, R.,
R. L. Davis,
D. Lockshon,
D. L. Turner, and H. Weintraub.
1990.
The protein Id: a negative regulator of helix-loop-helix DNA binding proteins.
Cell
61:49-59[Medline].
|
| 5.
|
Braun, B. S.,
R. Frieden,
S. L. Lessnick,
W. A. May, and C. T. Denny.
1995.
Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis.
Mol. Cell. Biol.
15:4623-4630[Abstract].
|
| 6.
|
Candido, E. P.,
R. Reeves, and J. R. Davie.
1978.
Sodium butyrate inhibits histone deacetylation in cultured cells.
Cell
14:105-113[Medline].
|
| 7.
|
Carter, R. S.,
P. Ordentlich, and T. Kadesch.
1997.
Selective utilization of basic helix-loop-helix-leucine zipper proteins at the immunoglobulin heavy-chain enhancer.
Mol. Cell. Biol.
17:18-23[Abstract].
|
| 8.
|
Chiaramello, A.,
K. Neuman,
K. Palm,
M. Metsis, and T. Neuman.
1995.
Helix-loop-helix transcription factors mediate activation and repression of the p75LNGFR gene.
Mol. Cell. Biol.
15:6036-6044[Abstract].
|
| 9.
|
Chu, C. C., and W. E. Paul.
1997.
FIG1, an interleukin 4 induced mouse B cell gene isolated by cDNA representational difference analysis.
Proc. Natl. Acad. Sci. USA
94:2507-2512[Abstract/Free Full Text].
|
| 10.
|
Condorelli, G.,
L. Vitelli,
M. Valtieri,
I. Marta,
E. Montesoro,
V. Lulli,
R. Baer, and C. Peschle.
1995.
Coordinate expression and developmental role of Id2 protein and TAL1/E2A heterodimer in erythroid progenitor differentiation.
Blood
86:164-175[Abstract/Free Full Text].
|
| 11.
|
Cooper, C. L.,
G. Brady,
F. Bilia,
N. N. Iscove, and P. J. Quesenberry.
1997.
Expression of the Id family of helix-loop-helix regulators during growth and development in the hematopoietic system.
Blood
89:3155-3165[Abstract/Free Full Text].
|
| 12.
|
Craig, J. E.,
J. Rochette,
M. Sampietro,
A. O. M. Wilkie,
R. Barnetson,
C. S. R. Hatton,
F. Demenias, and S. L. Thein.
1997.
Genetic heterogeneity in heterocellular hereditary persistence of fetal hemoglobin.
Blood
90:428-434[Abstract/Free Full Text].
|
| 13.
|
Darkin-Rattray, S. J.,
A. M. Gurnett,
R. W. Myers,
P. M. Dulski,
T. M. Crumley,
J. J. Allocco,
C. Cannova,
P. T. Meinke,
S. L. Colletti,
J. D. Poliskook, and D. M. Schmatz.
1996.
Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase.
Proc. Natl. Acad. Sci. USA
93:13143-13147[Abstract/Free Full Text].
|
| 14.
|
Economou, E. P.,
S. E. Antonarakis,
H. H. Kazazian, Jr.,
G. R. Serjeant, and G. J. Dover.
1991.
Variation in hemoglobin F production among normal and sickle cell adults is not related to nucleotide substitutions in the gamma promoter regions.
Blood
77:174-177[Abstract/Free Full Text].
|
| 15.
|
Elnitski, L.,
W. Millers, and R. Hardison.
1997.
Conserved E boxes function as part of the enhancer in hypersensitive site 2 of the b-globin locus control region.
J. Biol. Chem.
272:369-378[Abstract/Free Full Text].
|
| 16.
|
Fibach, E.,
P. Prasanna,
G. P. Rodgers, and D. Samid.
1993.
Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia.
Blood
82:2203-2209[Abstract/Free Full Text].
|
| 17.
|
Hawley, R. G.,
F. H. L. Lieu,
A. Z. C. Fong, and T. S. Hawley.
1994.
Versatile retroviral vectors for potential use in gene therapy.
Gene Ther.
1:136-138[Medline].
|
| 18.
|
Hsu, H.-L.,
L. Huang,
J. T. Tsan,
W. Funk,
W. E. Wright,
J.-S. Hu,
R. E. Kingston, and R. Baer.
1994.
Preferred sequences for DNA recognition by the TAL1 helix-loop-helix proteins.
Mol. Cell. Biol.
14:1256-1265[Abstract/Free Full Text].
|
| 19.
|
Hubank, M., and D. G. Schatz.
1994.
Identifying differences in mRNA expression by representational difference analysis of cDNA.
Nucleic Acids Res.
22:5640-5648[Abstract/Free Full Text].
|
| 20.
|
Jane, S. M., and J. M. Cunningham.
1996.
Molecular mechanisms of hemoglobin switching.
Int. J. Biochem. Cell. Biol.
28:1197-1209[Medline].
|
| 21.
|
Jane, S. M.,
P. A. Ney,
E. F. Vanin,
D. L. Gumucio, and A. W. Nienhuis.
1992.
Identification of a stage selector element in the human g-globin gene promoter that fosters preferential interaction with the 5' HS2 enhancer when in competition with the b-promoter.
EMBO J.
11:2961-2969[Medline].
|
| 22.
|
Jane, S. M.,
A. W. Nienhuis, and J. M. Cunningham.
1995.
Hemoglobin switching in man and chicken is mediated by a heteromeric complex between the ubiquitous transcription factor CP2 and a developmentally specific protein.
EMBO J.
14:97-105[Medline].
|
| 23.
|
Kreider, B.,
R. Benezra,
G. Rovera, and T. Kadesh.
1992.
Inhibition of myeloid differentiation by the helix-loop-helix protein Id.
Science
255:1700-1702[Abstract/Free Full Text].
|
| 24.
|
Lam, L. T., and E. H. Bresnick.
1996.
A novel DNA-binding protein, HS2NF5, interacts with a functionally important sequence of the human b-globin locus control region.
J. Biol. Chem.
271:32421-32429[Abstract/Free Full Text].
|
| 25.
|
Lasser, A. B.,
J. N. Buskin,
D. Lockshon,
R. L. David,
S. Apone,
S. D. Hauschka, and H. Weintraub.
1989.
MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatinine kinase enhancer.
Cell
58:823-831[Medline].
|
| 26.
|
Lewis, B. C.,
H. Shim,
Q. Li,
C. S. Wu,
L. A. Lee,
A. Maity, and C. V. Dang.
1997.
Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene.
Mol. Cell. Biol.
17:4967-4978[Abstract].
|
| 27.
|
Lisitsyn, N., and M. Wigler.
1993.
Cloning the differences between two complex genomes.
Science
259:946-951[Abstract].
|
| 28.
|
Lister, J.,
W. C. Forrester, and M. H. Baron.
1995.
Inhibition of an erythroid differentiation switch by the helix-loop-helix protein Id1.
J. Biol. Chem.
270:17939-17946[Abstract/Free Full Text].
|
| 29.
|
Lozzio, B. B., and C. B. Lozzio.
1979.
Properties and usefulness of the original K-562 human myelogenous leukemia cell line.
Leuk. Res.
3:363-370[Medline].
|
| 30.
|
McCaffrey, P. G.,
D. A. Newsome,
E. Fibach,
M. Yoshida, and M. S.-S. Su.
1997.
Induction of g-globin by histone deacetylase inhibitors.
Blood
90:2075-2083[Abstract/Free Full Text].
|
| 31.
|
Murre, C.,
P. S. McCaw, and D. Baltimore.
1989.
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins.
Cell
56:777-783[Medline].
|
| 32.
|
Murre, C.,
P. S. McCaw,
H. Vaessin,
M. Caudy,
L. Y. Jan,
C. V. Cabrera,
J. N. Buskin,
S. D. Hauschka,
A. B. Lassar,
H. Weintraub, and D. Baltimore.
1989.
Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence.
Cell
58:537-544[Medline].
|
| 33.
|
Noguchi, C. T.,
G. P. Rodgers,
G. Serjeant, and A. N. Schechter.
1988.
Levels of fetal hemoglobin necessary for treatment of sickle cell disease.
N. Engl. J. Med.
318:96-99[Medline].
|
| 34.
|
Nuez, B.,
D. Michalovich,
A. Bygrave,
R. Ploemacher, and F. Grosveld.
1995.
Defective hematopoiesis in fetal liver resulting from inactivation of the EKLF gene.
Nature
375:316-318[Medline].
|
| 35.
|
Orkin, S. H.
1995.
Regulation of globin gene expression in erythroid cells.
Eur. J. Biochem.
231:271-281[Medline].
|
| 36.
|
Pace, B. S.,
Q. Li, and G. Stamatoyannopoulos.
1996.
In vivo search for butyrate responsive sequences using transgenic mice carrying A gamma gene promoter mutants.
Blood
88:1079-1084[Abstract/Free Full Text].
|
| 37.
|
Perkins, A. C.,
A. H. Sharpe, and S. H. Orkin.
1995.
Lethal b-thalassemia in mice lacking the erythroid CACCC-transcription factor EKLF.
Nature
375:318-322[Medline].
|
| 38.
|
Persons, D. A.,
J. A. Allay,
E. R. Allay,
R. J. Smeyne,
R. A. Ashmun,
B. P. Sorrentino, and A. W. Nienhuis.
1997.
Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo.
Blood
90:1777-1786[Abstract/Free Full Text].
|
| 39.
|
Poncz, M. P.,
P. Henthorn,
C. Stoekert, and S. Surrey.
1989.
Globin gene expression in hereditary persistence of fetal hemoglobin and  o-thalassemia, p. 163-203.
In
N. McLean (ed.), Oxford surveys of eukaryotic genes. Oxford University Press, Oxford, United Kingdom.
|
| 40.
|
Safaya, S.,
A. Ibrahim, and R. F. Rieder.
1994.
Augmentation of g-globin gene promoter activity by carboxylic acids and components of the human b-globin locus control region.
Blood
84:3929-3935[Abstract/Free Full Text].
|
| 41.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 42.
|
Stamatoyannopoulos, G., and A. W. Nienhuis.
1994.
Hemoglobin switching, p. 67-105.
In
G. Stamatoyannopoulos, A. W. Nienhuis, P. W. Majerus, and H. Varmus (ed.), The molecular basis of blood diseases. W. B. Saunders, Philadelphia, Pa.
|
| 43.
|
Struhl, K.
1998.
Histone acetylation and transcriptional regulatory mechanisms.
Genes Dev.
12:599-606[Free Full Text].
|
| 44.
|
Sun, X.-H.,
N. G. Copeland,
N. A. Jenkins, and D. Baltimore.
1991.
Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins.
Mol. Cell. Biol.
11:5603-5611[Abstract/Free Full Text].
|
| 45.
|
Sun, X.-H.
1994.
Constitutive expression of the Id1 gene impairs mouse B cell development.
Cell
79:893-900[Medline].
|
| 46.
|
Vettese-Dadey, M.,
P. A. Grant,
T. R. Hebbes,
C. Crane-Robinson,
C. D. Allis, and J. L. Workman.
1996.
Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro.
EMBO J.
15:2508-2518[Medline].
|
| 47.
|
Wright, W. E.,
M. Binder, and W. Funk.
1991.
Cyclic amplification and selection of targets (CASTing) for the myogenin consensus binding site.
Mol. Cell. Biol.
11:4104-4110[Abstract/Free Full Text].
|
Molecular and Cellular Biology, June 1999, p. 4182-4190, Vol. 19, No. 6
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sripichai, O., Kiefer, C. M., Bhanu, N. V., Tanno, T., Noh, S.-J., Goh, S.-H., Russell, J. E., Rognerud, C. L., Ou, C.-N., Oneal, P. A., Meier, E. R., Gantt, N. M., Byrnes, C., Lee, Y. T., Dean, A., Miller, J. L.
(2009). Cytokine-mediated increases in fetal hemoglobin are associated with globin gene histone modification and transcription factor reprogramming. Blood
114: 2299-2306
[Abstract]
[Full Text]
-
Bank, A.
(2006). Regulation of human fetal hemoglobin: new players, new complexities. Blood
107: 435-443
[Abstract]
[Full Text]
-
Dempsey, N. J., Ojalvo, L. S., Wu, D. W., Little, J. A.
(2003). Induction of an embryonic globin gene promoter by short-chain fatty acids. Blood
102: 4214-4222
[Abstract]
[Full Text]
-
Langenfeld, E. M., Calvano, S. E., Abou-Nukta, F., Lowry, S. F., Amenta, P., Langenfeld, J.
(2003). The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis
24: 1445-1454
[Abstract]
[Full Text]
-
Gabbianelli, M., Testa, U., Massa, A., Morsilli, O., Saulle, E., Sposi, N. M., Petrucci, E., Mariani, G., Peschle, C.
(2003). HbF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with low-dose dexamethasone. Blood
101: 2826-2832
[Abstract]
[Full Text]
-
Holmes, M. L., Bartle, N., Eisbacher, M., Chong, B. H.
(2002). Cloning and Analysis of the Thrombopoietin-induced Megakaryocyte-specific Glycoprotein VI Promoter and Its Regulation by GATA-1, Fli-1, and Sp1. J. Biol. Chem.
277: 48333-48341
[Abstract]
[Full Text]
-
Vadolas, J., Wardan, H., Orford, M., Voullaire, L., Zaibak, F., Williamson, R., Ioannou, P. A.
(2002). Development of sensitive fluorescent assays for embryonic and fetal hemoglobin inducers using the human beta -globin locus in erythropoietic cells. Blood
100: 4209-4216
[Abstract]
[Full Text]
-
Harju, S., McQueen, K. J., Peterson, K. R.
(2002). Chromatin Structure and Control of {beta}-Like Globin Gene Switching. Exp. Biol. Med.
227: 683-700
[Abstract]
[Full Text]
-
Zhou, W., Clouston, D. R., Wang, X., Cerruti, L., Cunningham, J. M., Jane, S. M.
(2000). Induction of Human Fetal Globin Gene Expression by a Novel Erythroid Factor, NF-E4. Mol. Cell. Biol.
20: 7662-7672
[Abstract]
[Full Text]
-
Gabbianelli, M., Testa, U., Massa, A., Pelosi, E., Sposi, N. M., Riccioni, R., Luchetti, L., Peschle, C.
(2000). Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate. Blood
95: 3555-3561
[Abstract]
[Full Text]
-
Norton, J.
(2000). ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J. Cell Sci.
113: 3897-3905
[Abstract]